Federated Hermes’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-4,522
Closed -$10.3K 2201
2024
Q2
$10.3K Buy
4,522
+2,490
+123% +$9.51K ﹤0.01% 1773
2024
Q1
$8.78K Buy
2,032
+613
+43% +$2.14K ﹤0.01% 1792
2023
Q4
$4.33K Sell
1,419
-1,855
-57% -$3.49K ﹤0.01% 1867
2023
Q3
$4.71K Buy
+3,274
New +$6.34K ﹤0.01% 1890
2022
Q3
Sell
-179,472
Closed -$887K 2269
2022
Q2
$887K Buy
179,472
+139,872
+353% +$775K ﹤0.01% 1188
2022
Q1
$301K Buy
39,600
+13,084
+49% +$124K ﹤0.01% 1540
2021
Q4
$271K Sell
26,516
-33,617
-56% -$428K ﹤0.01% 1594
2021
Q3
$807K Buy
+60,133
New +$980K ﹤0.01% 1363
2021
Q1
Sell
-25,188
Closed -$453K 2365
2020
Q4
$453K Sell
25,188
-398,023
-94% -$5.95M ﹤0.01% 1537
2020
Q3
$4.89M Buy
423,211
+234,045
+124% +$3.86M 0.01% 733
2020
Q2
$4.59M Buy
189,166
+141,296
+295% +$2.34M 0.01% 738
2020
Q1
$528K Buy
+47,870
New +$894K ﹤0.01% 1360
2019
Q4
Sell
-20,015
Closed -$456K 2323
2019
Q3
$456K Buy
20,015
+18,183
+993% +$573K ﹤0.01% 1466
2019
Q2
$56K Sell
1,832
-207
-10% -$4.36K ﹤0.01% 1661
2019
Q1
$34K Buy
2,039
+1,011
+98% +$19.2K ﹤0.01% 1697
2018
Q4
$20K Sell
1,028
-74,048
-99% -$2.77M ﹤0.01% 1775
2018
Q3
$3.93M Buy
75,076
+21,217
+39% +$1.16M 0.01% 879
2018
Q2
$2.34M Buy
+53,859
New +$2.31M 0.01% 948

Federated Hermes's GTHX Position: Q3 2024 in Review

Federated Hermes sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 4,522 shares — an estimated $10.3K sold.

Federated Hermes first reported a position in GTHX in Q2 2018 and held it in 18 quarters. The position peaked at $4.89M in Q3 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Federated Hermes reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Federated Hermes sold 4,522 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $10.3K.
  • Federated Hermes first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
  • Federated Hermes's G1 Therapeutics, Inc. Common Stock position peaked at $4.89M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Federated Hermes's 13F filing for Q3 2024, filed 13 Nov 2024.